Sep 3 |
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
Aug 20 |
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex
|
Aug 16 |
Quince reports data from Phase III Ataxia-Telangiectasia treatment trial
|
Aug 15 |
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
|
Aug 13 |
Quince Therapeutics GAAP EPS of -$0.64
|
Aug 13 |
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
|
Jun 26 |
Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial
|
Jun 25 |
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
|
Jun 4 |
FDA fast tracks Quince Therapeutics’ rare ataxia drug EryDex
|
Jun 3 |
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
|